Little Apellis is arming itself for a David and Goliath battle over a blockbuster drug franchise
Is a little biotech like Apellis $APLS ready for a David vs. Goliath commercial battle with a well-established pharma player and their ferocious Big Pharma buyer waiting in the wings?
That’s the $39 billion question for AstraZeneca, which will still be closing on its big Alexion buyout as the biotech counts down to a looming May 14 PDUFA date on its prospective rival as the FDA wraps a priority review of pegcetacoplan, a C3 drug that’s been aiming at toppling the long reigning C5 complement inhibitor champ Soliris and its successor Ultomiris for rare cases of PNH — paroxysmal nocturnal hemoglobinuria.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
